Aligos therapeutics strengthens board with two new independent directors

South san francisco, calif., aug. 08, 2024 (globe newswire) --  aligos therapeutics, inc. (nasdaq: algs, “aligos”, the “company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of heather preston, m.d. and margarita chavez, j.d. as class ii independent directors to the board of directors, effective august 7, 2024. dr. preston will join the nominating and corporate governance committee as chair and ms. chavez will join the audit committee.
ALGS Ratings Summary
ALGS Quant Ranking